HER2 作为结直肠癌的预测性生物标志物和治疗靶点。
HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
机构信息
Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO), Université Catholique de Louvain, Brussels, Belgium.
Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO), Université Catholique de Louvain, Brussels, Belgium.
出版信息
Clin Colorectal Cancer. 2020 Jun;19(2):65-72. doi: 10.1016/j.clcc.2020.02.007. Epub 2020 Feb 8.
The prognosis of metastatic colorectal cancer (mCRC) is poor. Cetuximab and panitumumab, 2 anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs), improve the overall survival of patients with RAS wild-type mCRC. However, not all patients with RAS wild-type mCRC will respond to anti-EGFR mAbs. Several retrospective trials suggest that human epidermal growth factor receptor 2 (HER2) amplification could be a predictive biomarker of resistance to anti-EGFR mAbs in patients with metastatic RAS and RAF wild-type mCRC. Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC. Although these findings need to be confirmed in randomized trials, the data strongly support that HER2 is an actionable gene in CRC and provide the scientific rationale to test HER2 status on a routine basis in this disease. In this review, we discuss the predictive value of HER2 activation in CRC as well as its potential role as a treatment target.
转移性结直肠癌（mCRC）的预后较差。西妥昔单抗和帕尼单抗这两种抗表皮生长因子受体（EGFR）单克隆抗体（mAb）可提高 RAS 野生型 mCRC 患者的总生存期。然而，并非所有 RAS 野生型 mCRC 患者都会对抗 EGFR mAb 产生应答。几项回顾性试验表明，人表皮生长因子受体 2（HER2）扩增可能是转移性 RAS 和 RAF 野生型 mCRC 患者对抗 EGFR mAb 耐药的预测生物标志物。曲妥珠单抗联合拉帕替尼或帕妥珠单抗的双重 HER2 抑制在 RAS 野生型 mCRC 中显示出有前景的初步抗肿瘤疗效。尽管这些发现需要在随机试验中得到证实，但这些数据强烈支持 HER2 是 CRC 中可靶向的基因，并为在该疾病中常规检测 HER2 状态提供了科学依据。在这篇综述中，我们讨论了 HER2 激活在 CRC 中的预测价值及其作为治疗靶点的潜在作用。
Zotero 插件